RxDoctor Payments Data

Michael Miranda, DO

Orthopaedic Surgery · Brandon, FLNPI 1225202575

Payments from drug & device makers

$138,420in general payments, 2019–2025

Across 217 payments — averaging $637.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Omnilife Science, Inc$66K
  • Corin USA$50K
  • Stryker$7K
  • Medical Device Business Services, Inc.$6K
  • Depuy Synthes Products, Inc.$4K
  • Zimmer Biomet$1K
  • plus $4K from 23 others
$8,629in research payments, 2019–2025

Across 7 payments — averaging $1232.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Omnilife Science, Inc$6K
  • Corin USA$2K

What the payments were for

  • Consulting fees$96,42173%
  • Travel & lodging$24,47318%
  • Food & beverage$11,8209%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,420 in reported general payments places this provider in the 85th percentile of 1,263 orthopaedic surgery providers in Florida.

See all orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$424,703
Medicare patients
599
Services billed
9,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban29$10,891
Celecoxib125$2,271
Enoxaparin Sodium16$2,177
Diclofenac Sodium65$2,130
Cephalexin203$1,781
Ondansetron Hcl237$1,209
Tramadol Hcl259$770
Oxycodone Hcl191$728
Meloxicam172$367
Clindamycin Hcl67$341
Amoxicillin191$189
Methylprednisolone21$151
Ciprofloxacin Hcl16$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$637$10,89129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,263 orthopaedic surgery providers in Florida.

Other orthopaedic surgery in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →